Abstract
Patients with ERBB2-positive, locally advanced or metastatic breast cancer benefit from continued trastuzumab, according to findings from the TBP phase III trial. Gunter von Minckwitz (Neu-Isenburg, Germany) and colleagues randomly assigned 156 patients, who had progressed on previous trastuzumab, to capecitabine alone or capecitabine and trastuzumab. After a median follow-up of 15·6 months, those in the combined group had a longer time to progression than those assigned to capecitabine alone (8·2 vs 5·6 months; hazard ratio [HR] 0·69 [CI 0·49–0·99]; p=0·0404).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
